文献速递小儿麻醉疼痛医学

特发性脊柱侧凸脊柱融合术后多模式镇痛实践、疼痛轨迹与康复趋势的多中心研究

Multi-Institutional Study of Multimodal Analgesia Practice, Pain Trajectories, and Recovery Trends After Spine Fusion for Idiopathic Scoliosis.
PubMed 文献 · Anesth Analg · 2025-01-02

该多中心队列纳入343例8-25岁接受后路脊柱融合术的特发性脊柱侧凸患者,描述围术期多模式镇痛管理及术后12个月疼痛、功能障碍与生活质量。各中心阿片类及非阿片类用药差异显著,住院阿片消耗逐年下降而急性或慢性疼痛无变化,慢性术后疼痛发生率为24.2%。

要点

  • 各中心围术期多模式镇痛用药差异显著(P < .001)。
  • 住院阿片消耗逐年下降(每年-0.08 MME/kg/POD 0-1),急性或慢性疼痛无变化。
  • 慢性术后疼痛(>3/10超过术后2个月)发生率为24.2%,约17%报告神经病理性疼痛。

核心结论

  • 多模式镇痛策略存在中心间差异,住院阿片消耗逐年下降但急性或慢性疼痛无变化。
  • 持续性疼痛发生率高,且与功能障碍和生活质量差相关,术后监测有助于功能康复。

研究设计与样本

  • 多中心队列研究,2016至2023年在美国6个中心招募8-25岁接受后路脊柱融合术的特发性脊柱侧凸患者343例,中位年龄15.2岁(IQR 13.7-16.6),女性占71.1%。
  • 收集术后第0和第1天疼痛、阿片消耗(静脉吗啡毫克当量/公斤)及非阿片类镇痛药使用数据;术前、术后2-6个月和10-12个月使用PainDETECT、FDI和PedsQL问卷评估。
  • 采用基于组的离散混合模型分析12个月疼痛轨迹;慢性术后疼痛定义为术后超过2个月疼痛评分>3/10。

主要发现

  • 围术期阿片类和非阿片类镇痛药使用在各中心间差异显著(P < .001)。
  • 术前48.2%(157/343)使用加巴喷丁类药物;术中瑞芬太尼输注264/337(78.3%)、芬太尼输注73/337(21.7%)、美沙酮推注159/338(47%);术后患者自控镇痛342/343(99.9%)。
  • 住院阿片消耗中位值逐年下降(每年-0.08 MME/kg/POD 0-1,SE 0.02,P < .001),同时氯胺酮、美沙酮、右美托咪定使用增加(均P < .001),区域镇痛增加(P = .015)。
  • 术后第0至1天中度至重度疼痛时间约占33%;慢性术后疼痛报告率为24.2%(64/264),约17%报告持续神经病理性/可能神经病理性疼痛。
  • 识别出4种术后疼痛轨迹,其中2种(71%)显示疼痛缓解,2种(29%)显示持续轻度及中度至重度疼痛;慢性术后疼痛组各时间点FDI更高(P < .001)、PedsQL更低(P = .001),但两组FDI和PedsQL均随时间改善(P < .001)。

关键数值与推荐

  • 慢性术后疼痛定义为术后超过2个月疼痛评分>3/10。
  • 住院阿片消耗采用静脉吗啡毫克当量/公斤(MME/kg)表示,统计术后第0至1天。

临床怎么用

  • 青少年及年轻成人特发性脊柱侧凸后路脊柱融合术后应进行术后疼痛与功能监测,以识别持续疼痛并促进功能恢复。
  • 多模式镇痛方案可因中心而异,住院阿片消耗下降未改变急慢性疼痛结局,需关注非阿片类辅助药物的合理使用。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posterior spinal fusion (PSF) surgery for correction of idiopathic scoliosis is associated with chronic postsurgical pain (CPSP). In this multicenter study, we describe perioperative multimodal analgesic (MMA) management and characterize postoperative pain, disability, and quality of life over 12 months after PSF in adolescents and young adults. METHODS: Subjects (8-25 years) undergoing PSF were recruited at 6 sites in the United States between 2016 and 2023. Data were collected on pain, opioid consumption (intravenous morphine milligram equivalents (MME)/kg), and use of nonopioid analgesics through postoperative days (POD) 0 and 1. Pain descriptors, functional disability, and quality of life were assessed preoperatively, 2 to 6 and 10 to 12 months after surgery using questionnaires (PainDETECT, Functional Disability Inventory [FDI], and Pediatric Quality of Life Inventory [PedsQL]). Descriptive analyses of analgesic use across and within sites (by preoperative pain and psychological diagnoses), acute postoperative pain and yearly in-hospital analgesic trends are reported. Pain trajectories over 12 months were analyzed using group-based discrete mixture. CPSP (defined as pain score >3/10 beyond 2 months postsurgery), and associated FDI and PedsQL were analyzed. RESULTS: In this cohort (343 patients, median [interquartile range {IQR}] 15.2 (13.7-16.6) years, 71.1% female), perioperative use of opioids and nonopioid analgesics significantly varied across sites ( P < .001). Preoperatively, gabapentinoids were administered to 48.2% (157/343). Intraoperatively, opioid use included remifentanil (264/337 [78.3%]) and fentanyl (73/337 [21.7%]) infusions, and methadone boluses (159/338 [47%]). Postoperatively, patient-controlled analgesia was commonly used (342/343 [99.9%]). Within sites MMA use did not appear to differ by preoperative pain or psychological comorbidities. Median in-hospital opioid use declined over time (-0.08 [standard error {SE} 0.02] MME/kg/POD 0 to 1 per year, P < .001) while increased use of ketamine ( P < .001), methadone ( P < .001), dexmedetomidine ( P < .001), and regional analgesia ( P = .015) was observed. Time spent in moderate-to-severe pain on POD 0 to 1 was ≈33%. CPSP was reported by 24.2% (64/264) with ~17% reporting ongoing neuropathic/likely neuropathic pain. Four postsurgical pain trajectories were identified; 2 (71%) showed resolving pain and 2 (29%) showed persistent mild and moderate-to-severe pain. Although FDI and PedsQL improved over time in both CPSP and non-CPSP groups ( P < .001), FDI was higher ( P < .001) and PedsQL lower ( P = .001) at each time point in the CPSP versus the non-CPSP group. CONCLUSIONS: MMA strategies showed site-specific variability and decreasing yearly trends of in-hospital opioid use without changes in acute or chronic pain after PSF. There was a high incidence of persistent pain associated with disability and poor quality of life warrants postoperative surveillance to enable functional recovery.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Einhorn LM, Monitto CL, Ganesh A, et al. Multi-Institutional Study of Multimodal Analgesia Practice, Pain Trajectories, and Recovery Trends After Spine Fusion for Idiopathic Scoliosis. Anesth Analg. 2025. PMID: 39745877. doi:10.1213/ANE.0000000000007351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。